NCT06576037 2025-10-15
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
M.D. Anderson Cancer Center
Helsinki University Central Hospital
Hoffmann-La Roche
Dana-Farber Cancer Institute
ASLAN Pharmaceuticals
PharmaEngine